Niels Moya

Rennes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis.

CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis.

Journal: Leukemia & lymphoma

Published: August 13, 2024

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

Journal: Blood advances

Published: June 13, 2024

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

Journal: British journal of haematology

Published: March 17, 2024

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Journal: British journal of haematology

Published: February 17, 2023

Hairy cell leukemia with isolated bone lesions.

Hairy cell leukemia with isolated bone lesions.

Journal: Clinical case reports

Published: January 01, 2023

Smoldering multiple myeloma: biology, clinical manifestations and management.

Smoldering multiple myeloma: biology, clinical manifestations and management.

Journal: Leukemia & lymphoma

Published: October 21, 2021

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article.

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article.

Journal: Cancers

Published: October 06, 2021

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.

Journal: Blood advances

Published: June 17, 2021

Waldenström macroglobulinemia and relationship to immune deficiency.

Waldenström macroglobulinemia and relationship to immune deficiency.

Journal: Leukemia & lymphoma

Published: June 04, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026